3,4,5-Trimethoxy-benzoesaeure-<3-brom-propylester> | 14037-86-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4,5-Trimethoxy-benzoesaeure-<3-brom-propylester>
• 英文别名: 3-Bromopropyl 3,4,5-trimethoxybenzoate
• CAS: 14037-86-6
• 化学式: C₁₃H₁₇BrO₅
• 分子量: 333.179
• InChiKey: WLHZTLVYOKJNLF-UHFFFAOYSA-N

物化性质

• 熔点：
  65-67 °C
• 沸点：
  368.8±21.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,4,5-Trimethoxy-benzoesaeure-<3-brom-propylester> 在 palladium on activated charcoal 甲酸铵 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 17.0h， 生成 3-[4-[3-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxypropyl]piperazin-1-yl]propyl 3,4,5-trimethoxybenzoate
  参考文献：
  名称：

  Exploratory Chemistry toward the Identification of a New Class of Multidrug Resistance Reverters Inspired by Pervilleine and Verapamil Models

  摘要：

  On the basis of the present knowledge of the substrate recognition site of ABC transporter proteins and inspired by the structures of verapamil and pervilleine A, a new class of Pgp-mediated multidrug resistance (MDR) reverters has been designed and synthesized. The new compounds are flexible molecules carrying one or two basic nitrogen atoms flanked, at properly modulated distance, by two aromatic moieties. Most of the molecules studied possess MDR inhibitory activity on anthracycline-resistant erythroleukemia K 562 cells, showing a potency that is higher than that of the reference compound verapamil and, in a few cases (7, 12, 13, 17, 20, 22, 28), is in the high nanomolar range. These compounds may be useful leads to develop new MDR reverting agents. In fact, the chemical structure of the class is fairly simple and can be implemented in a variety of ways that will allow the synthesis of new compounds that might be useful leads for the development of drugs to control Pgp-dependent MDR.

  DOI：

  10.1021/jm050542x
• 作为产物：
  描述：

  没食子酸 在 水 、 caesium carbonate 、 sodium iodide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 48.0h， 生成 3,4,5-Trimethoxy-benzoesaeure-<3-brom-propylester>
  参考文献：
  名称：

  一种具有抗癌活性的五倍子酸酰化衍生物及 其应用

  摘要：

  一种具有抗癌活性的五倍子酸酰化衍生物，其结构式为：本发明提供的酰化衍生物对口腔癌细胞具有良好的活性，且选择性强，具有良好的临床应用价值。

  公开号：

  CN106496035B

文献信息

• New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells
  作者：Laura Braconi、Elisabetta Teodori、Chiara Riganti、Marcella Coronnello、Alessio Nocentini、Gianluca Bartolucci、Marco Pallecchi、Marialessandra Contino、Dina Manetti、Maria Novella Romanelli、Claudiu T. Supuran、Silvia Dei

  DOI：10.1021/acs.jmedchem.2c01175

  日期：2022.11.10

  continuing search of dual P-gp and hCA XII inhibitors, we synthesized and studied new N,N-bis(alkanol)amine aryl diester derivatives characterized by the presence of a coumarin group. These hybrids contain both P-gp and hCA XII binding groups to synergistically overcome the P-gp-mediated multidrug resistance (MDR) in cancer cells expressing both P-gp and hCA XII. Indeed, hCA XII modulates the efflux activity

  在持续寻找双重 P-gp 和 hCA XII 抑制剂的过程中，我们合成并研究了新的N、N-双（链烷醇）胺芳基二酯衍生物，其特征在于存在香豆素基团。这些杂交体包含 P-gp 和 hCA XII 结合基团，以协同克服表达 P-gp 和 hCA XII 的癌细胞中 P-gp 介导的多药耐药性 (MDR)。实际上，hCA XII 调节 P-gp 的外排活性，抑制 hCA XII 会降低细胞内 pH，从而降低 P-gp 的 ATP 酶活性。所有化合物均对 P-gp 和 hCA XII 蛋白单独显示出抑制活性，其中许多化合物在过表达 P-gp 和 hCA XII 的 HT29/DOX 和 A549/DOX 细胞中表现出协同作用，比 K562/仅过表达 P-gp 的 DOX 细胞。化合物5和14被鉴定为有前途的化学增敏剂，用于选择性抑制过度表达 P-gp 和 hCA XII 的 MDR 癌细胞。
• Trialkoxybenzoyloxyalkyl derivatives related to norharman
  申请人：SEARLE &

  公开号：US02852520A1

  公开（公告）日：1958-09-16
• Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters
  作者：Silvia Dei、Marcella Coronnello、Elisa Floriddia、Gianluca Bartolucci、Cristina Bellucci、Luca Guandalini、Dina Manetti、Maria Novella Romanelli、Milena Salerno、Ivan Bello、Enrico Mini、Elisabetta Teodori

  DOI：10.1016/j.ejmech.2014.09.084

  日期：2014.11

  As a continuation of our research on potent and efficacious P-gp-dependent multidrug resistance (MDR) reversers, several new N,N-bis(alkanol)amine aryl esters were designed and synthesized, varying the aromatic moieties or the length of the methylenic chain. The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay, where most of the new compounds were shown to be active. In particular the asymmetrical compounds, characterized by two linkers of different length, generally showed fairly high activities as MDR reversers. Some selected compounds (isomers 15-17) were further studied by evaluating their doxorubicin cytotoxicity enhancement (reversal fold, RF) on the K562/DOX cell line. The results of both pharmacological assays indicate that compounds 16 (GDE6) and 17 (GDE19) could be interesting leads for the development of new P-gp dependent MDR modulators. (C) 2014 Elsevier Masson SAS. All rights reserved.
• �ber pharmakodynamisch wirksame 3,4,5-Trimethoxybenzoate und verwandte Ester von symmetrischen Bis-hydroxyalkylpiperazinen und-dialkylpolymethylendiaminen
  作者：K. Schl�gl、Rosemarie Schl�gl

  DOI：10.1007/bf00908805

  日期：——
• Kralt,T. et al., Recueil des Travaux Chimiques des Pays-Bas, 1961, vol. 80, p. 330 - 357
  作者：Kralt,T. et al.

  DOI：——

  日期：——